PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10711629-0	2000	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen"s disease patients.	Thalidomide	14-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	60-76	
12060642-1	2002	PURPOSE: This research investigated the biotransformation of thalidomide by cytochrome P-450 (CYP).	Thalidomide	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	76-92	
12060642-1	2002	PURPOSE: This research investigated the biotransformation of thalidomide by cytochrome P-450 (CYP).	Thalidomide	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97	
12060642-2	2002	EXPERIMENTAL DESIGN: We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated metabolism of thalidomide.	Thalidomide	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	102-105	
12060642-2	2002	EXPERIMENTAL DESIGN: We used liver microsomes from humans and/or animals and the recombinant specific CYP isozymes to investigate CYP-mediated metabolism of thalidomide.	Thalidomide	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	130-133	
9493761-17	1998	Examples of human teratogens that are substrates for CYP enzymes include thalidomide, phenytoin, ethanol, and several hormonal agents.	Thalidomide	73-84	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-56	
23165864-8	2013	Genetic factors including single nucleotide polymorphisms (SNPs) that change cytochrome P450 (CYP) activity and epigenetic regulation that modifies CYP expression levels may contribute to the changes in pharmacokinetics and adverse drug reactions (ADRs) of thalidomide.	Thalidomide	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97	
23165864-8	2013	Genetic factors including single nucleotide polymorphisms (SNPs) that change cytochrome P450 (CYP) activity and epigenetic regulation that modifies CYP expression levels may contribute to the changes in pharmacokinetics and adverse drug reactions (ADRs) of thalidomide.	Thalidomide	257-268	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-151